Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL422079 | 0.81 | CYP2C9 (0.48) | KCNH2CYP2C9KCNE1CCR1KCNQ1 | |
| SCHEMBL63981 | 0.80 | KCNH2 (0.49) | KCNH2CYP2C9KCNE1CCR1KCNQ1 | |
| SCHEMBL63268 | 0.80 | KCNH2 (0.53) | KCNH2CYP2C9KCNE1CCR1KCNQ1 | |
| SCHEMBL418372 | 0.79 | KCNH2 (0.47) | KCNH2CYP2C9KCNE1CCR1KCNQ1 | |
| SCHEMBL421852 | 0.79 | CYP2C9 (0.49) | KCNH2CYP2C9KCNE1CCR1KCNQ1 | |
| SCHEMBL422080 | 0.79 | KCNH2 (0.50) | KCNH2CYP2C9KCNE1CCR1KCNQ1 | |
| SCHEMBL421835 | 0.79 | CYP2C9 (0.47) | KCNH2CYP2C9KCNE1CCR1KCNQ1 | |
| SCHEMBL62484 | 0.79 | KCNH2 (0.47) | KCNH2CYP2C9KCNE1CCR1KCNQ1 | |
| SCHEMBL52889 | 0.79 | KCNH2 (0.50) | KCNH2CYP2C9KCNE1CCR1KCNQ1 | |
| SCHEMBL418769 | 0.78 | KCNH2 (0.48) | KCNH2CYP2C9KCNE1CCR1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022045-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | VENKATRAMAN SHANKAR (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022045-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | CCND3, CDK3, CDK2 | KCNH2 2502/4885CYP2C9 1960/4885KCNE1 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.